Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 728 participants.

Also called NCT05065216

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 728 participants (planned count) (from the registry)
Sponsor
DiaMedica Therapeutics Inc (from the registry)
Registry
  • NCT NCT05065216
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Canada, France, Georgia, Hungary, Poland, Romania, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05065216. Randomized; double masking; primary purpose treatment. Start 2021-11-07 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Acronym
ReMEDy2
Condition
Acute Stroke
Condition
Stroke
Intervention (Drug)
Recombinant human tissue kallikrein
Intervention (Other)
Placebo for DM199 Solution for Injection
Lead sponsor
DiaMedica Therapeutics Inc (class: industry)

Record details

Record id
cardio:ct-nct05065216
Content hash
9b283a4fe21e76eca0fb72a72af064daad330d1974bd5b68ac284abd6370f0f9